Recruiting

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(21 sites)

United States

Orange County Research Center, Lake Forest, California

Translational Clinical Research LLC, Aventura, Florida

Destiny Research Center, Palmetto Bay, Florida

ClinCept, LLC, Columbus, Georgia

Chesapeake Clinical Research Inc, White Marsh, Maryland

Brigham and Womens Hospital, Boston, Massachusetts

Mayflower Clinical, South Dartmouth, Massachusetts

Mayo Clinic, Rochester, Minnesota

Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota

University of North Carolina Clinical and Translational Research Center, Chapel Hill, North Carolina

Monroe Biomedical Research, Monroe, North Carolina

North Carolina Clinical Research, Raleigh, North Carolina

Allergy Asthma and Clinical Research Center, Oklahoma City, Oklahoma

Monroe Biomedical Research, North Charleston, South Carolina

Endeavor Clinical Trials, San Antonio, Texas

Australia

Clinical Medical and Analytical eXellence CMAX, Adelaide, South Australia

Belgium

Algemeen Ziekenhuis Sint Maarten-Emmaus vzw, Mechelen

Canada

Winchester District Memorial Hospital, Winchester, Ontario

United Kingdom

VPD Heart and Lung Research Institute, Cambridge

Chelsea and Westminster Hospital, London

The Medicines Evaluation Unit, Manchester